OIG report looks positive for DexCom, says BofA

After the Office of Inspector General report on Medicare payments for continuous glucose monitors and supplies came out, BofA noted that the report is just the OIG’s recommendation to CMS and is not an update to the CMS proposal regarding competitive bidding from July. With that said, the firm views the OIG report positively for DexCom (DXCM) as it shows Class 2 supplies are priced fairly to in line with Medicare expectations, adds the analyst, who maintains a Buy rating and $10 price target on the shares.